Literature DB >> 28419426

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Juan-Carlos Hernández-Boluda1, Juan-Gonzalo Correa2, Alberto Alvarez-Larrán3, Francisca Ferrer-Marín4, José-María Raya5, Joaquín Martínez-López6, Patricia Velez7, Manuel Pérez-Encinas8, Natalia Estrada9, Valentín García-Gutiérrez10, María-Laura Fox11, Elisa Luño12, Ana Kerguelen13, Beatriz Cuevas14, María-Antonia Durán15, María-José Ramírez16, Maite Gómez-Casares17, María-Isabel Mata-Vázquez18, Anabel Regadera19, Arturo Pereira20, Francisco Cervantes2.   

Abstract

Entities:  

Keywords:  bleeding; myelofibrosis; prognosis; thrombocytopenia; treatment

Mesh：

Year:  2017        PMID： 28419426     DOI： 10.1111/bjh.14601

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Authors:  Claire N Harrison; Donal P McLornan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  Lucia Masarova; Ahmad Alhuraiji; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2018-01-17       Impact factor: 2.997

3.  Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Authors:  Aaron T Gerds; Michael R Savona; Bart L Scott; Moshe Talpaz; Miklos Egyed; Claire N Harrison; Abdulraheem Yacoub; Alessandro Vannucchi; Adam J Mead; Jean-Jacques Kiladjian; Jennifer O'Sullivan; Valentin García-Gutiérrez; Prithviraj Bose; Raajit K Rampal; Carole B Miller; Jeanne Palmer; Stephen T Oh; Sarah A Buckley; Diane R Mould; Kaori Ito; Shanthakumar Tyavanagimatt; Jennifer A Smith; Karisse Roman-Torres; Sri Devineni; Adam R Craig; John O Mascarenhas
Journal:  Blood Adv       Date:  2020-11-24

4.  Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Authors:  Srdan Verstovsek; Ruben Mesa; Moshe Talpaz; Jean-Jacques Kiladjian; Claire N Harrison; Stephen T Oh; Alessandro M Vannucchi; Raajit Rampal; Bart L Scott; Sarah A Buckley; Adam R Craig; Karisse Roman-Torres; John O Mascarenhas
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 5.  Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.

Authors:  Vikas Gupta; Sonia Cerquozzi; Lynda Foltz; Christopher Hillis; Rebecca Devlin; Mahmoud Elsawy; Kuljit Grewal; Caroline Hamm; Caroline McNamara; Shireen Sirhan; Brian Leber
Journal:  JCO Oncol Pract       Date:  2020-03-05

6.  Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.

Authors:  Lucia Masarova; Ruben Anthony Mesa; Juan C Hernández-Boluda; Jason A Taylor
Journal:  Leuk Res       Date:  2020-02-26       Impact factor: 3.156

7.  [A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees].

Authors:  Z F Xu; T J Qin; H L Zhang; L W Fang; N B Hu; L J Pan; S Q Qu; B Li; X Yan; Z X Shi; H J Huang; D Liu; Y N Cai; Y D Zhang; P H Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14

8.  Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.

Authors:  Ronda Copher; Arianna Kee; Aaron Gerds
Journal:  Oncologist       Date:  2022-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.